Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02569632 · ClinicalTrials.gov registry record · Phase 4
Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)
A Phase 4 study, sponsored by UCSF Benioff Children's Hospital Oakland.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT02569632: Completed Phase 4 study, sponsored by UCSF Benioff Children's Hospital Oakland.
NCT02569632 is a Phase 4 study that has completed, run by UCSF Benioff Children's Hospital Oakland. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02569632, a Phase 4 study, has completed, sponsored by UCSF Benioff Children's Hospital Oakland.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will investigate the breadth of protection against meningococcal disease in humans immunized with a newly FDA approved meningococcal B vaccine, trade name "Trumenba®" manufactured by Pfizer Vaccines. As a secondary goal the investigators will investigate underlying mechanisms by which human anti-FHbp antibodies elicit complement-mediated bactericidal activity.
Interventions
- BIOLOGICAL Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02569632
The ClinicalTrials.gov registry entry for NCT02569632 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCSF Benioff Children's Hospital Oakland, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals) is the first listed.
NCT02569632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02569632 about?
NCT02569632 is a clinical study titled "Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)". This study will investigate the breadth of protection against meningococcal disease in humans immunized with a newly FDA approved meningococcal B vaccine, trade name "Trumenba®" manufactured by Pfizer Vaccines. As a secondary goal the investigators will investigate underlying mechanisms by which hum...
What is the current status of trial NCT02569632?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2015-01. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02569632?
The interventions under investigation include: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02569632?
This trial is sponsored by UCSF Benioff Children's Hospital Oakland, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.